New England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
Roche(RHHBY) GlobeNewswire News Room·2024-10-31 14:00
ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one of the most commonly mutated genes in HR-positive disease2 Basel, 31 October 2024 - Roche (SIX: RO, ROG; ...